141136-83-6

Basic information

• Product Name: TRAP-6
• Synonyms: H-SER-PHE-LEU-LEU-ARG-ASN-OH;TRAP-6;TRAP-6SER-PHE-LEU-LEU-ARG-ASN;THROMBIN RECEPTOR (42-47), HUMAN;THROMBIN RECEPTOR ACTIVATOR FOR PEPTIDE 6;THROMBIN RECEPTOR ACTIVATOR PEPTIDE 6;SER-PHE-LEU-LEU-ARG-ASN;SFLLRN
• CAS NO: 141136-83-6
• Molecular Formula: C34H56N10O9
• Molecular Weight: 748.87
• Product Categories: peptide;amino
• Mol File: 141136-83-6.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: −20°C
• Solubility: TFA 0.1%: soluble
• Water Solubility: Soluble in water at 1mg/ml
• CAS DataBase Reference: TRAP-6(CAS DataBase Reference)
• NIST Chemistry Reference: TRAP-6(141136-83-6)
• EPA Substance Registry System: TRAP-6(141136-83-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 141136-83-6(Hazardous Substances Data)

Usage

Description

TRAP-6, or Thrombin Receptor Activator Peptide 6, is a PAR-1-activating peptide that plays a crucial role in protecting astrocytes from cell death, particularly in conditions associated with hypoglycemia. It is known to induce aggregation and impair adhesion to collagen under flow conditions.

Uses

Used in Pharmaceutical Industry:
TRAP-6 is used as a therapeutic agent for the protection of astrocytes from cell death, specifically in hypoglycemic conditions. Its ability to induce aggregation and impair adhesion to collagen under flow conditions makes it a valuable compound in the development of treatments for neurological disorders and conditions related to astrocyte dysfunction.
Used in Research and Development:
In the field of research and development, TRAP-6 serves as an essential tool for studying the mechanisms underlying astrocyte cell death and hypoglycemia. It can be utilized in various experimental setups to investigate the effects of hypoglycemia on astrocytes and to explore potential therapeutic strategies for mitigating cell death and improving overall brain health.
Used in Drug Delivery Systems:
Similar to gallotannin, TRAP-6 can also be incorporated into novel drug delivery systems to enhance its applications and efficacy. These systems can be designed to improve the delivery, bioavailability, and therapeutic outcomes of TRAP-6, particularly in the context of neurological disorders and conditions involving astrocyte dysfunction.

Biochem/physiol Actions

Hexapeptide fragment of the thrombin receptor (residues 42-47). Shown to activate the thrombin receptor and cause platelet aggregation (EC50 = 0.8 μM).